慢性肾脏病中的肺动脉高压、右心室重构与结局
肺动脉高压(PH,平均肺动脉压>20 mm Hg)在CKD患者中常见,患病率随肾功能下降而升高,并与心血管并发症和死亡风险增加相关。由于右心导管检查研究稀少,CKD中PH的血流动力学表型数据匮乏;左心衰竭、贫血和动静脉内瘘可能参与PH发生,右心室代偿性肥厚和扩张最终导致心衰和死亡。目前尚无针对CKD人群PH的特异性治疗评估,需更多纵向右心室变化及治疗试验研究。
要点
- CKD患者PH患病率随肾功能下降而增加,并与心血管事件和死亡风险升高相关。
- 左心衰竭、贫血和动静脉内瘘可能促进CKD患者PH发生。
- CKD中PH治疗证据缺乏,优化容量管理、减少高流量内瘘和肾移植可能有益。
核心结论
- PH在CKD患者中常见且与不良结局相关,但血流动力学表型和右心室纵向变化数据匮乏,尚无特异性治疗证据。
研究设计与样本
- 综述性文章,总结CKD中PH的患病率、病理生理、右心室重构及治疗现状,未报告系统检索范围。
主要发现
- PH定义为平均肺动脉压>20 mm Hg,患病率随肾功能下降而增加,与心血管并发症和死亡风险升高相关。
- 右心导管检查研究稀少导致CKD中PH血流动力学表型数据稀疏。
- 左心衰竭、贫血和动静脉内瘘可能参与CKD中PH的发生。
- 肺动脉压升高引起右心室肥厚和扩张等适应不良改变,最终导致临床心衰和死亡。
关键数值与推荐
- PH定义为平均肺动脉压>20 mm Hg。
- 肺动脉高压治疗药物在晚期CKD患者中的角色不明确,因多数临床试验排除晚期CKD患者。
临床怎么用
- 对CKD患者应关注PH相关因素如左心衰竭、贫血和动静脉内瘘。
- 可考虑优化容量管理、减少高流量动静脉内瘘流量和肾移植以减轻PH影响。
局限性
- 缺乏右心导管检查数据,CKD中PH血流动力学表型资料稀疏。
- 缺乏CKD中PH患者右心室纵向变化数据。
- 肺动脉高压治疗药物在CKD中的证据不足,因晚期CKD患者被多数试验排除。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pulmonary hypertension (PH), defined as a mean pulmonary artery pressure >20 mm Hg, is a common comorbidity in patients with CKD. The prevalence of PH increases as kidney function declines, and PH is associated with a higher risk of cardiovascular complications and mortality. The pathophysiology of PH in CKD has not been studied in detail primarily because studies incorporating right heart catheterization, the gold-standard test for diagnosing and phenotyping PH, are rare, and therefore, data regarding the hemodynamic phenotypes of PH in patients with CKD are sparse. Factors such as left-sided heart failure, anemia, and the presence of arteriovenous fistulas all likely play a role in the development of PH in patients with CKD. As pressures in the pulmonary arteries increase, maladaptive changes, such as hypertrophy and dilation, occur in the right ventricle to maintain cardiac output, eventually leading to clinical heart failure and death. Although this pathologic cycle is well characterized in patients with pulmonary arterial hypertension, there are few data on longitudinal changes in the RV in patients with PH and CKD. There are no specific treatments that have been evaluated for PH in the CKD population although there are several strategies which may mitigate the effects of PH including improved volume management, reduction in flow of high-flow arteriovenous fistulas, and potentially kidney transplantation. The role of medications used for pulmonary arterial hypertension in patients with CKD is unclear because patients with advanced CKD were excluded from most clinical trials of these therapies. More research is needed including the characterization of longitudinal right ventricular changes in patients with CKD, refinement of the molecular pathways implicated in the pathogenesis of PH, fistula flow rates which put patients at risk for the development of PH, and clinical trials of PH therapies in patients with CKD.
引用
- Tuttle M, Ruopp NF, Sarnak MJ, et al. Pulmonary Hypertension, Right Ventricular Remodeling and Outcomes in CKD. Clin J Am Soc Nephrol. 2026. PMID: 42507489. doi:10.2215/CJN.0000001198
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。